Brexucabtagene autoleucel (Tecartus) was the sole CAR T cell therapy recognized for the treatment of individuals with mantle cell lymphoma (MCL), which targeted CD19 [105]. This evidence concerns the gene CD19 and mantle cell lymphoma.